Cargando…
TB research requires strong protections, innovation, and increased funding in response to COVID-19
Autores principales: | Nyang’wa, B. T., LaHood, A. N., Mitnick, C. D., Guglielmetti, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164060/ https://www.ncbi.nlm.nih.gov/pubmed/34051826 http://dx.doi.org/10.1186/s13063-021-05331-4 |
Ejemplares similares
-
Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO
por: Stringer, Beverley, et al.
Publicado: (2021) -
Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
por: LaHood, Allison, et al.
Publicado: (2022) -
Funding social innovation for health with research funds for development
por: Akuffo, Hannah, et al.
Publicado: (2020) -
Association of BMI Category Change with TB Treatment Mortality in HIV-Positive Smear-Negative and Extrapulmonary TB Patients in Myanmar and Zimbabwe
por: Benova, Lenka, et al.
Publicado: (2012) -
Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)